News
Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.
Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...
Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant improvements in both progression-free survival and objective response rate in ...
Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its progression into Phase III clinical development.
Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL ...
Roche presented results from the phase III SUNMO [NCT05171647] study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin) demonstrated a ...
“Lunsumio and Polivy represent the first combination of a bispecific antibody and antibody-drug conjugate, which could avoid chemotherapy and potentially provide an alternative option for some ...
“Lunsumio and Polivy represent the first combination of a bispecific antibody and antibody-drug conjugate, which could avoid chemotherapy and potentially provide an alternative option for some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results